EUVIMEDOpdag EUVIMED
Übersichtsarbeit

CXCR4/CXCL12 axis: “old” pathway as “novel” target for anti‐inflammatory drug discovery

Liuxin Lu, Junjie Li, Xiaoying Jiang, Renren Bai iD

Medicinal Research Reviews · 2024

DOI: 10.1002/med.22011 ↗

At a glance

Übersichtsarbeit in Medicinal Research Reviews, 2024. Written by Liuxin Lu and 3 co-authors. Institution: Department of Medicinal Chemistry, School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, China. Major MEDLINE topics: Receptors, CXCR4, HIV Infections. Cited 49 times so far (Crossref); 201 references. Funded by: National Natural Science Foundation of China, Scientific Research Foundation for Scholars of HZNU.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Inflammation is the body's defense response to exogenous or endogenous stimuli, involving complex regulatory mechanisms. Discovering anti‐inflammatory drugs with both effectiveness and long‐term use safety is still the direction of researchers' efforts. The inflammatory pathway was initially identified to be involved in tumor metastasis and HIV infection. However, research in recent years has proved that the CXC chemokine receptor type 4 (CXCR4)/CXC motif chemokine ligand 12 (CXCL12) axis plays a critical role in the upstream of the inflammatory pathway due to its chemotaxis to inflammatory cells. Blocking the chemotaxis of inflammatory cells by CXCL12 at the inflammatory site may block and alleviate the inflammatory response. Therefore, developing CXCR4 antagonists has become a novel strategy for anti‐inflammatory therapy. This review aimed to systematically summarize and analyze the mechanisms of action of the CXCR4/CXCL12 axis in more than 20 inflammatory diseases, highlighting its crucial role in inflammation. Additionally, the anti‐inflammatory activities of CXCR4 antagonists were discussed. The findings might help generate new perspectives for developing anti‐inflammatory drugs targeting the CXCR4/CXCL12 axis.

Subjects

MeSH terms (MEDLINE)

Receptors, CXCR4HIV InfectionsHumansChemokine CXCL12InflammationAnti-Inflammatory AgentsDrug Discovery

Author keywords

CXCL12CXCR4chemokinesdrug discoveryinflammatory disease

Substances

Receptors, CXCR4Chemokine CXCL12Anti-Inflammatory AgentsCXCL12 protein, humanCXCR4 protein, human

Authors and institutions

  • Department of Medicinal Chemistry, School of Pharmacy, Hangzhou Normal University, Hangzhou, Zhejiang, China.
  • Key Laboratory of Elemene Class Anti-tumor Chinese Medicines, Engineering Laboratory of Development and Application of Traditional Chinese Medicines, Collaborative Innovation Center of Traditional Chinese Medicines of Z…

ORCID profiles: Renren Bai

Funding

  • National Natural Science Foundation of China
  • Scientific Research Foundation for Scholars of HZNU

Cite

APA

Lu, L., Li, J., Jiang, X., & Bai, R. (2024). CXCR4/CXCL12 axis: “old” pathway as “novel” target for anti‐inflammatory drug discovery. Medicinal Research Reviews. https://doi.org/10.1002/med.22011

Vancouver

Lu L, Li J, Jiang X, Bai R. CXCR4/CXCL12 axis: “old” pathway as “novel” target for anti‐inflammatory drug discovery. Medicinal Research Reviews. 2024. doi:10.1002/med.22011

BibTeX
@article{Lu2024,
  author = {Lu, Liuxin and Li, Junjie and Jiang, Xiaoying and Bai, Renren},
  title = {CXCR4/CXCL12 axis: “old” pathway as “novel” target for anti‐inflammatory drug discovery},
  journal = {Medicinal Research Reviews},
  year = {2024},
  doi = {10.1002/med.22011}
}
Start for free →